Article
Cell Biology
Tian-Yi Jiang, Xiao-Wen Cui, Tian-Mei Zeng, Yu-Fei Pan, Yun-Kai Lin, Xiao-fan Feng, Ye-Xiong Tan, Zhen-gang Yuan, Li-Wei Dong, Hong-Yang Wang
Summary: The deficiency of PTEN is correlated with the improved efficacy of gemcitabine-based chemotherapy in cholangiocarcinoma (CCA). PTEN deficiency or down-regulation enhances gemcitabine efficacy by directly binding to and dephosphorylating the catalytic subunit of protein phosphatase 2A (PP2Ac), leading to increased enzymatic activity and diminished phosphorylation of deoxycytidine kinase (DCK). Thus, PTEN deficiency and high phosphorylation of DCK can predict a better response to gemcitabine-based chemotherapy in CCA.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Murray F. Brennan, Peter J. Allen, William R. Jarnagin
Summary: Operations for pancreatic neoplasms have made significant progress in the past 50 years, thanks to innovation. Molecular diagnosis has enabled the identification of different types of tumors with varying natural progressions. Observation is now a viable strategy for certain cysts and neuroendocrine neoplasms. However, finding a long-term cure for ductal pancreatic adenocarcinoma is still a challenge.
JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Surgery
Bradley N. Reames, Alex B. Blair, Robert W. Krell, Vincent P. Groot, Georgios Gemenetzis, James C. Padussis, Sarah P. Thayer, Massimo Falconi, Christopher L. Wolfgang, Matthew J. Weiss, Chandrakanth Are, Jin He
Summary: There is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC among an international cohort of pancreas surgeons. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of resectability.
Article
Biochemistry & Molecular Biology
Mika Hosokawa, Risako Seiki, Seigo Iwakawa, Ken-ichi Ogawara
Summary: The study revealed that DAC resistance is mainly caused by attenuated dCK rather than increased CDA. Additionally, the combination of AC and polyphenols may be a promising alternative to tackle DAC resistance.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Immunology
Florencia Aybar, Maria Julia Perez, Maria Silvina Marcora, Maria Eugenia Samman, Mariano Marrodan, Juana Maria Pasquini, Jorge Correale
Summary: Cladribine (2CdA) is a synthetic drug that reduces immune cells related to multiple sclerosis. It has been found to have effects on microglial cells, including inhibiting proliferation, inducing apoptosis, and reducing cytokine production. However, it has limited effects on astrocytes.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Emily Truong, Stephen Pandol, Christie Jeon
Summary: This review examines the role of pancreatic steatosis in the development of pancreatic cancer through epidemiological studies and experimental animal models. It highlights the prevalence of pancreatic steatosis and its association with pancreatic cancer. The review also explores the cellular mechanisms underlying pancreatic steatosis and its impact on the tumor microenvironment, as well as the effects of bariatric surgery. Additionally, it identifies gaps in current knowledge and proposes future research directions for understanding the mechanisms of other obesity-associated cancers.
Article
Oncology
Malcolm J. Moore, David Goldstein, John Hamm, Arie Figer, Joel R. Hecht, Steven Gallinger, Heather J. Au, Pawel Murawa, David Walde, Robert A. Wolff, Daniel Campos, Robert Lim, Keyue Ding, Gary Clark, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy Parulekar
Summary: Adding the HER1/EGFR-targeted agent erlotinib to gemcitabine significantly improved overall survival and progression-free survival in patients with advanced pancreatic cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Hiromichi Murase, Yoichi Matsuo, Yuki Denda, Keisuke Nonoyama, Tomokatsu Kato, Yoshinaga Aoyama, Yuichi Hayashi, Hiroyuki Imafuji, Kenta Saito, Mamoru Morimoto, Ryo Ogawa, Hiroki Takahashi, Akira Mitsui, Masahiro Kimura, Shuji Takiguchi
Summary: Pancreatic cancer is resistant to chemotherapy and has a poor prognosis. The prognostic factor ILK was found to be upregulated in a gemcitabine-resistant pancreatic cancer cell line. The ILK inhibitor Cpd22 showed antitumor effects in both gemcitabine-sensitive and gemcitabine-resistant cells.
Review
Oncology
Milena Muzzolini, Raphael L. C. Araujo, T. Peter Kingham, Frederique Peschaud, Francois Paye, Renato M. Lupinacci
Summary: This study systematically reviewed the literature on chyle leak after pancreatectomy and proposed a management algorithm based on the available evidence. The results showed that the extent of surgery is the most common predictor of risk, and conservative treatment has been shown to be effective in most cases.
Article
Biochemistry & Molecular Biology
Yejin Jang, Jin Soo Shin, Myoung Kyu Lee, Eunhye Jung, Timothy An, Uk-Il Kim, Kyungjin Kim, Meehyein Kim
Summary: The study found that gemcitabine has high antiviral activity against SARS-CoV-2, while 2FdC has lower antiviral activity. Both compounds showed low cytotoxicity towards cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Verona Buocikova, Silvia Tyciakova, Eleftherios Pilalis, Chara Mastrokalou, Maria Urbanova, Miroslava Matuskova, Lucia Demkova, Veronika Medova, Eleonora Marta Longhin, Elise Runden-Pran, Maria Dusinska, Ivan Rios-Mondragon, Mihaela Roxana Cimpan, Alena Gabelova, Andrea Soltysova, Bozena Smolkova, Aristotelis Chatziioannou
Summary: DAC, in combination with traditional anticancer drugs, shows promise as a treatment option for solid tumors. Increasing DCK expression to potentiate DAC's effect did not lead to changes in global DNA methylation levels or cell viability.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Julie Bulsei, Andrea Chierici, Marco Alifano, Antonio Castaldi, Celine Drai, Serena De Fatico, Edoardo Rosso, Eric Fontas, Antonio Iannelli
Summary: This study evaluated the effect of bariatric surgery on pancreatic cancer incidence in individuals with obesity. It found that bariatric surgery has a protective effect against pancreatic cancer in the 18-50 years population. However, further high-quality prospective studies are needed to confirm these results.
Article
Medicine, Research & Experimental
Ji Eun Lee, Pureunchowon Lee, Young-Chan Yoon, Beom Seok Han, Soyeon Ko, Min Seok Park, Yun Ji Lee, Sang Eun Kim, Ye Jin Cho, Joo Han Lim, Ji-Kan Ryu, Soyeon Shim, Dae-Kee Kim, Kyung Hee Jung, Soon-Sun Hong
Summary: Pancreatic ductal adenocarcinoma (PDAC) is characterized by excessive production of transforming growth factor beta (TGF-beta), resulting in tumor progression and resistance to gemcitabine. A small-molecule TGF-beta receptor I kinase inhibitor, vactosertib, demonstrated synergistic anticancer effects with gemcitabine by inhibiting viability, decreasing expression of ECM components, inducing apoptosis, and inhibiting migration and invasion in pancreatic cancer cells. The combination treatment also suppressed tumor growth and inhibited the TGF-beta/Smad2 signaling pathway. These findings suggest that vactosertib and gemcitabine may be a potential treatment option for pancreatic cancer patients.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Emma Grant, Fatma Bucklain, Lucy E. Ginn, Peter C. Laity, Barbara C. Ciani, Helen C. Bryant
Summary: This study developed in vitro models that mimic the stiffness of normal and cancerous breast tissue, and found that breast cancer cells showed resistance to gemcitabine at higher stiffness. The study also revealed that the use of selective progesterone receptor modulators could reduce resistance to gemcitabine.
Review
Surgery
Jean Gugenheim, Anna Crovetto, Niccolo Petrucciani
Summary: Multimodal treatment, including surgery and chemotherapy, is considered the gold standard for pancreatic cancer. Neoadjuvant therapy has shown promise for resectable, borderline resectable, and locally advanced cases. Recent studies support the use of neoadjuvant therapy in borderline resectable pancreatic cancers, with ongoing trials evaluating its role in resectable cases.
UPDATES IN SURGERY
(2022)
Letter
Oncology
Yana Debie, Timon Vandamme, Maria E. Goossens, Peter A. van Dam, Marc Peeters
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Giacomo Bregni, Andrea Pretta, Chiara Senti, Elena Acedo Reina, Caroline Vandeputte, Elena Trevisi, Paraskevas Gkolfakis, Pashalina Kehagias, Amelie Deleporte, Jean-Luc Van Laethem, Philippe Vergauwe, Marc Van den Eynde, Guido Deboever, Jos Janssens, Gauthier Demolin, Stephane Holbrechts, Marylene Clausse, Thierry De Grez, Marc Peeters, Lionel D'Hondt, Karen Geboes, Tatiana Besse-Hammer, Francoise Rothe, Patrick Flamen, Alain Hendlisz, Francesco Sclafani
Summary: This study is the first to investigate circulating tumor DNA (ctDNA) in the neoadjuvant setting of early-stage colon cancer. The results suggest that baseline circulating-free DNA is an independent prognostic factor for disease-free survival (DFS), and changes in circulating-free DNA between baseline and surgery may also be associated with prognosis. Additionally, the detection of ctDNA before surgery was not associated with outcome, but an increase in ctDNA levels between baseline and surgery may indicate worse 5-year DFS.
Article
Otorhinolaryngology
Margot Baudelet, Frederic Duprez, Leen Van den Steen, Sandra Nuyts, Daan Nevens, Ann Goeleven, Caroline Vandenbruaene, Hanne Massonet, Alice Vergauwen, Heleen Bollen, Sarah Deschuymer, Kristien Wouters, Marc Peeters, Carl Van Laer, Steven Marien, Michiel Van den Brekel, Lisette van der Molen, Tom Vauterin, Joost van Dinther, Hilde Verstraete, Isabel Hutsebaut, Sabine Meersschout, Olivier Vanderveken, Marc De Bodt, Gwen Van Nuffelen
Summary: This multicenter RCT investigated the effect of three different service-delivery modes on patients' adherence to prophylactic swallowing exercises during radiotherapy. The study found that adherence decreased over time in all groups, but the therapist-supported group achieved the highest adherence rates. Increasing face-to-face contact with a speech-language therapist can overcome the problem of low adherence in this population.
Review
Oncology
Joe Ibrahim, Marc Peeters, Guy Van Camp, Ken Op de Beeck
Summary: The recent increase in cancer biomarker research has led to new insights in the field. Technological breakthroughs, such as long read sequencing and microarrays, have enabled high throughput profiling of biomarkers, while advances in bioinformatic tools have made reliable and accurate biomarkers a reality. These changes have renewed interest in biomarker research and provided opportunities for enhancing cancer management and early disease detection.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Yana Debie, Jonas R. M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Arien, Sebastien Anguille, Annelies Janssens, Hans Prenen, Evelien L. J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam
Summary: Patients with cancer have reduced humoral responses after double-dose COVID-19 vaccination, but their cellular response is comparable to healthy individuals. A third dose of BNT162b2 can boost immune responses in both healthy people and cancer patients. This study compares the effects of a third dose of BNT162b2 after homologous (double-dose BNT162b2) and heterologous (ChAdOx1) vaccination in cancer patients.
CLINICAL CANCER RESEARCH
(2023)
Letter
Oncology
Yana Debie, Peter A. van Dam, Maria E. Goossens, Marc Peeters, Timon Vandamme
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters
Summary: One of the major challenges in digestive oncology is selecting the optimal therapy for RAS-mutated metastatic colorectal cancer (mCRC). Recent developments in targeting the RAS-pathway have shown promising results and may lead to clinical benefits for patients in the coming years. Although resistance remains a concern, strategic combination regimens have been developed to overcome this issue. In this review, we summarize the standard of care and discuss emerging therapies for RAS-mutated mCRC.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Marc Peeters, Hans-Peter Lipp, Minjeong Park, Ye Chan Yoon, Dirk Arnold
Summary: SB8 is a biosimilar of bevacizumab that has been extensively studied to demonstrate its similarity in various aspects. It is authorized for use in different types of tumors based on the concept of extrapolation. Additionally, SB8 offers the advantage of prolonged stability in diluted form compared to the reference bevacizumab. Although there are concerns about extrapolation, the "totality of evidence" supports the biosimilarity of SB8.
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study provides evidence that left-sided colorectal cancer has a significantly better prognosis compared to right-sided colorectal cancer, in all stages and ages combined. The survival of left-sided colorectal cancer is also longer than right-sided colorectal cancer in stage IV, regardless of MMR, RAS, and BRAF status.
Article
Microbiology
Baptiste Oosterlinck, Hannah Ceuleers, Wout Arras, Joris G. De Man, Karen Geboes, Heiko De Schepper, Marc Peeters, Sarah Lebeer, Jurgita Skieceviciene, Georgina L. Hold, Juozas Kupcinskas, Alexander Link, Benedicte Y. De Winter, Annemieke Smet
Summary: This study identified the mucin-microbiome signatures in gastric adenocarcinomas and their impact on clinical outcomes. The findings showed that intestinal mucin phenotype and high-level MUC13 expression were associated with poor survival, while gastric MUC5AC or MUC6 abundance was associated with a more favorable outcome. Furthermore, oral bacteria such as Neisseria, Prevotella, and Veillonella were found to play a potential role in MUC13 signaling and were associated with intestinal and mixed mucin phenotype tumors.
Article
Chemistry, Medicinal
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke
Summary: The lack of solid data and prospective studies has resulted in a lack of clear guidelines for cardiovascular monitoring in patients receiving immune checkpoint inhibitors (ICIs). In order to address this issue, we have initiated the CAVACI trial to investigate the short- and long-term cardiovascular effects of ICIs. Patient recruitment started in January 2022.
Article
Oncology
Valerie Desmedt, Aranzazu Jauregui-Amezaga, Liselotte Fierens, Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, Joao Sabino, Lara Crape, Michael Somers, Anne Hoorens, Joris Dutre, Triana Lobaton
Summary: This paper provides updated practice advice on the diagnosis and management of immune checkpoint inhibitor-induced gastrointestinal toxicity for gastroenterologists and oncologists. The use of immune checkpoint inhibitors in cancer immunotherapy has been shown to increase overall survival, but it also carries the risk of severe immune-mediated adverse events, particularly involving the gastrointestinal tract. The paper emphasizes the importance of early multidisciplinary approach and proposes criteria for diagnosis and treatment.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Laura Marien, Odeta Islam, Siddharth Chhajlani, Willem Lybaert, Marc Peeters, Guy Van Camp, Ken Op de Beeck, Timon Vandamme
Summary: Given the considerable heterogeneity in neuroendocrine neoplasms, there is a need for multiple biomarkers to capture different aspects of these tumors. Circulating biomarkers, such as NETest and ctDNA-based analysis, show promise in enhancing accuracy of diagnosis, prognosis determination, and therapy prediction and monitoring.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study confirms that left-sided colorectal cancer has a better prognosis compared to right-sided colorectal cancer in the Belgian population. The presence of biomarkers such as MMR, BRAF, and RAS status does not significantly affect the prognostic effect of primary tumor location.
Meeting Abstract
Oncology
Ivana Gorbaslieva, Dana Mustafa, Robin Colenbier, Marc Peeters, Dirk Ysebaert, Vera Saldien, Luigi Brancato, Oleg Rudenko, Johan Van den Bossche, John Paul Bogers